A randomized trial of rizatriptan in migraine attacks in children

    Research output: Contribution to journalArticleScientificpeer-review

    Abstract

    "Objective: To examine the efficacy of rizatriptan and the consistency of treatment response in migraine attacks of children and adolescents. Methods: We conducted a double-blind, placebo-controlled three-way crossover trial in patients ages 6 to 17 years diagnosed with migraine in two pediatric hospital outpatient clinics. Two doses of rizatriptan and a matching placebo were administered at home during three attacks. Rizatriptan dose was 5 mg for those with a body weight of 20 to 39 kg, and 10 mg for those with a body weight of 40 kg or more. The primary efficacy endpoint was headache relief by two grades on a five-grade face scale at 2 hours. Results: Ninety-six patients used all three treatments, 10 used two, and 10 only the first. At 2 hours, the primary endpoint was reached twice as often after both treatments of rizatriptan (first 74%, n = 71/96; second 73%, n = 70/96) as after placebo (36%, n = 35/96) (p < 0.001). Already at 1 hour, rizatriptan was clearly more effective as headache relief was reported by 50% (n = 48/96) and 55% (n = 53/96) of children after the first and the second dose of rizatriptan, compared to 29% (n = 28/96) after placebo (p = 0.004). Rizatriptan was superior at 3 and 4 hours, and the other endpoints also favored rizatriptan. Efficacy of rizatriptan was constant over the two treated attacks, and the findings were similar in children using the dose of 5 and 10 mg. No serious adverse effects were observed. Conclusions: Oral rizatriptan is effective and well-tolerated for migraine attacks in children over age 6 years."
    Original languageEnglish
    JournalNeurology
    Volume67
    Issue number7
    Pages (from-to)1135-1140
    Number of pages6
    ISSN0028-3878
    DOIs
    Publication statusPublished - 2006
    MoE publication typeA1 Journal article-refereed

    Fields of Science

    • 111 Mathematics
    • 3124 Neurology and psychiatry

    Cite this

    @article{222724b22ce64b54acada73d30046720,
    title = "A randomized trial of rizatriptan in migraine attacks in children",
    abstract = "{"}Objective: To examine the efficacy of rizatriptan and the consistency of treatment response in migraine attacks of children and adolescents. Methods: We conducted a double-blind, placebo-controlled three-way crossover trial in patients ages 6 to 17 years diagnosed with migraine in two pediatric hospital outpatient clinics. Two doses of rizatriptan and a matching placebo were administered at home during three attacks. Rizatriptan dose was 5 mg for those with a body weight of 20 to 39 kg, and 10 mg for those with a body weight of 40 kg or more. The primary efficacy endpoint was headache relief by two grades on a five-grade face scale at 2 hours. Results: Ninety-six patients used all three treatments, 10 used two, and 10 only the first. At 2 hours, the primary endpoint was reached twice as often after both treatments of rizatriptan (first 74{\%}, n = 71/96; second 73{\%}, n = 70/96) as after placebo (36{\%}, n = 35/96) (p < 0.001). Already at 1 hour, rizatriptan was clearly more effective as headache relief was reported by 50{\%} (n = 48/96) and 55{\%} (n = 53/96) of children after the first and the second dose of rizatriptan, compared to 29{\%} (n = 28/96) after placebo (p = 0.004). Rizatriptan was superior at 3 and 4 hours, and the other endpoints also favored rizatriptan. Efficacy of rizatriptan was constant over the two treated attacks, and the findings were similar in children using the dose of 5 and 10 mg. No serious adverse effects were observed. Conclusions: Oral rizatriptan is effective and well-tolerated for migraine attacks in children over age 6 years.{"}",
    keywords = "111 Mathematics, 3124 Neurology and psychiatry",
    author = "Kati Ahonen and H{\"a}m{\"a}l{\"a}inen, {Mirja L} and Mervi Eerola and Kalle Hoppu",
    year = "2006",
    doi = "10.1212/01.wnl.0000238179.79888.44",
    language = "English",
    volume = "67",
    pages = "1135--1140",
    journal = "Neurology",
    issn = "0028-3878",
    publisher = "Lippincott williams & wilkins",
    number = "7",

    }

    A randomized trial of rizatriptan in migraine attacks in children. / Ahonen, Kati; Hämäläinen, Mirja L; Eerola, Mervi; Hoppu, Kalle.

    In: Neurology, Vol. 67, No. 7, 2006, p. 1135-1140.

    Research output: Contribution to journalArticleScientificpeer-review

    TY - JOUR

    T1 - A randomized trial of rizatriptan in migraine attacks in children

    AU - Ahonen, Kati

    AU - Hämäläinen, Mirja L

    AU - Eerola, Mervi

    AU - Hoppu, Kalle

    PY - 2006

    Y1 - 2006

    N2 - "Objective: To examine the efficacy of rizatriptan and the consistency of treatment response in migraine attacks of children and adolescents. Methods: We conducted a double-blind, placebo-controlled three-way crossover trial in patients ages 6 to 17 years diagnosed with migraine in two pediatric hospital outpatient clinics. Two doses of rizatriptan and a matching placebo were administered at home during three attacks. Rizatriptan dose was 5 mg for those with a body weight of 20 to 39 kg, and 10 mg for those with a body weight of 40 kg or more. The primary efficacy endpoint was headache relief by two grades on a five-grade face scale at 2 hours. Results: Ninety-six patients used all three treatments, 10 used two, and 10 only the first. At 2 hours, the primary endpoint was reached twice as often after both treatments of rizatriptan (first 74%, n = 71/96; second 73%, n = 70/96) as after placebo (36%, n = 35/96) (p < 0.001). Already at 1 hour, rizatriptan was clearly more effective as headache relief was reported by 50% (n = 48/96) and 55% (n = 53/96) of children after the first and the second dose of rizatriptan, compared to 29% (n = 28/96) after placebo (p = 0.004). Rizatriptan was superior at 3 and 4 hours, and the other endpoints also favored rizatriptan. Efficacy of rizatriptan was constant over the two treated attacks, and the findings were similar in children using the dose of 5 and 10 mg. No serious adverse effects were observed. Conclusions: Oral rizatriptan is effective and well-tolerated for migraine attacks in children over age 6 years."

    AB - "Objective: To examine the efficacy of rizatriptan and the consistency of treatment response in migraine attacks of children and adolescents. Methods: We conducted a double-blind, placebo-controlled three-way crossover trial in patients ages 6 to 17 years diagnosed with migraine in two pediatric hospital outpatient clinics. Two doses of rizatriptan and a matching placebo were administered at home during three attacks. Rizatriptan dose was 5 mg for those with a body weight of 20 to 39 kg, and 10 mg for those with a body weight of 40 kg or more. The primary efficacy endpoint was headache relief by two grades on a five-grade face scale at 2 hours. Results: Ninety-six patients used all three treatments, 10 used two, and 10 only the first. At 2 hours, the primary endpoint was reached twice as often after both treatments of rizatriptan (first 74%, n = 71/96; second 73%, n = 70/96) as after placebo (36%, n = 35/96) (p < 0.001). Already at 1 hour, rizatriptan was clearly more effective as headache relief was reported by 50% (n = 48/96) and 55% (n = 53/96) of children after the first and the second dose of rizatriptan, compared to 29% (n = 28/96) after placebo (p = 0.004). Rizatriptan was superior at 3 and 4 hours, and the other endpoints also favored rizatriptan. Efficacy of rizatriptan was constant over the two treated attacks, and the findings were similar in children using the dose of 5 and 10 mg. No serious adverse effects were observed. Conclusions: Oral rizatriptan is effective and well-tolerated for migraine attacks in children over age 6 years."

    KW - 111 Mathematics

    KW - 3124 Neurology and psychiatry

    U2 - 10.1212/01.wnl.0000238179.79888.44

    DO - 10.1212/01.wnl.0000238179.79888.44

    M3 - Article

    VL - 67

    SP - 1135

    EP - 1140

    JO - Neurology

    JF - Neurology

    SN - 0028-3878

    IS - 7

    ER -